Thyrocare Technologies Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹187Cr
- +21.4% YoY
- +12.7% QoQ
- Net profit
- ₹22Cr
- +29.4% YoY
- +15.8% QoQ
- Margin
- 30%
- +8 pp YoY
- +5 pp QoQ
Guidance rank: #16 of 34 in Healthcare Services
See the sector's top 10 — free with your mobile number.
The short version
Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.
From Thyrocare Technologies Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%.
- Volume growth anticipated around 14%, aligned closely with revenue growth due to tiered pricing structure, with no material price increases expected.
- Franchisee network set to expand with plans to add 1,500 to 2,000 new franchise partners annually, supporting growth over next 3-5 years.
- Partnership business growing strongly, including health tech and corporate/insurance segments, aiding volume and revenue expansion.
- Continued focus on specialized test menu expansion, including allergy and genomics, poised to drive higher realization and growth.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For FY '25, capex was roughly INR 40-50 crores annually.
- The company has sufficient cash flow to manage capex and acquisitions without stress.
- No large amount has been set aside for acquisitions in FY '26; expected deployment around INR 15-20 crores focused on weaker geographies (Gujarat, Rajasthan, Northeast).
- The company pursues a “string of pearls” acquisition strategy—small, focused acquisitions rather than large deals, due to management bandwidth considerations.
- Capital investment in Nueclear centers is not planned currently, as a new center setup costs around INR 10 crores; focus remains on maintaining and optimizing existing centers.
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Thyrocare Technologies Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 187 | 154 | +21.4% | 166 | +12.7% |
| Operating profit (EBITDA) | 57 | 34 | +67.6% | 42 | +35.7% |
| Operating margin | 30% | 22% | +8 pp | 25% | +5 pp |
| Profit before tax | 47 | 23 | +104.3% | 28 | +67.9% |
| Net profit (PAT) | 22 | 17 | +29.4% | 19 | +15.8% |
| EPS (₹) | 1.36 | 1.12 | +21.4% | 1.20 | +13.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- 3B Blackbio (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
- Apollo Hospitals (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
- Narayana Hrudaya (Q4 FY25)
Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q4 FY25 results?
Mid-teens revenue growth expected for FY '26, with cautious optimism due to a high current base and industry growth of 10-11%. Revenue growth guidance for FY '26 is mid-teens percentage, reflecting cautious optimism due to a high base and competitive pressure.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a neutral. The stock trades at a P/E of 52.8 with a market cap of ₹9,550 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
For FY '25, capex was roughly INR 40-50 crores annually.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
